NCT06434090View on ClinicalTrials.gov

Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

June 5, 2024

Primary Completion Date

June 5, 2025

Study Completion Date

July 1, 2026

Conditions
Colorectal Cancer
Interventions
DRUG

Liposomal irinotecan

Liposomal irinotecan will be given biweekly at a dose from 70mg/m2 to 90mg/m2.

DRUG

Bevacizumab

bevacizumab will be given biweekly at a dose of 5mg/m2

Trial Locations (1)

510655

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT06434090 - Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter